Design of probiotic bacteria to promote digestive and metabolic health

益生菌的设计促进消化和代谢健康

• 批准号: 549693-2020
• 负责人: Philpott, Dana
• 金额: $ 21.87万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=699047
• 关键词: Design; probiotic; bacteria; promote; digestive

The gut microbiota plays a key role in strengthening the gut barrier by stimulating protective responses from the human intestine. Loss of epithelial barrier integrity, also known as a leaky gut can lead to low-grade inflammation and is linked to the development of a number of chronic diseases in humans, from inflammatory bowel disease (IBD) and metabolic syndrome/type 2 diabetes to Parkinsons disease, chronic kidney disease and even certain cancers. Because of its far-reaching impact on these chronic diseases, there is an unmet need to develop new strategies to counteract the detrimental systemic consequences of a leaky gut. In this project, we will design probiotic bacteria that will increase the levels of a microbial product, called MDP, which targets a host protein called NOD2. We have shown that NOD2 activation can fight against a leaky gut and promote healing of the intestinal lining after injury. At the same time, NOD2 triggering can also improve metabolic health. Consequently, these probiotics could be used to protect and treat individuals with gut-related problems as well as metabolic diseases, such as type 2 diabetes.

肠道微生物群在通过刺激保护性免疫增强肠道屏障方面起着关键作用。 人体肠道的反应。上皮屏障完整性丧失，也称为渗漏 肠道可以导致低度炎症，并与许多疾病的发展有关。 人类慢性疾病，包括炎症性肠病（IBD）和代谢性疾病 综合征/2型糖尿病到帕金森病，慢性肾病，甚至某些 癌的由于其对这些慢性病的深远影响， 需要制定新的战略，以抵消全球化的有害系统性后果， 肠漏在这个项目中，我们将设计益生菌， 一种名为MDP的微生物产物，靶向一种名为NOD 2的宿主蛋白。我们已经表明 NOD 2的激活可以对抗肠道渗漏，促进肠道内壁的愈合， 伤后同时，NOD 2触发也可以改善代谢健康。 因此，这些益生菌可用于保护和治疗与肠道相关的个体。 问题以及代谢疾病，如2型糖尿病。